STOCK TITAN

ReWalk Robotics to Report Third Quarter 2023 Financial Results on November 14, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
ReWalk Robotics Ltd. will release its third quarter 2023 financial results on November 14, 2023, and host a conference call and live webcast to discuss the results.
Positive
  • None.
Negative
  • None.

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its third quarter 2023 financial results on Tuesday, November 14, 2023, prior to the U.S. financial markets open.

Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following:

Toll free (U.S.)1-833-316-0561
International (U.S)1-412-317-0690
Germany0800-6647650
Israel1-809-212373
Access CodePlease reference the “ReWalk Robotics Ltd. Call”
  

The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at rewalk.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/ihgeu9si/.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com.

ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.

ReWalk Media Relations:
LifeSci Communications
E: media@rewalk.com

ReWalk Investor Contact:
Mike Lawless
CFO
ReWalk Robotics
E: investorrelations@rewalk.com 


FAQ

When will ReWalk Robotics Ltd. release its third quarter 2023 financial results?

ReWalk Robotics Ltd. will release its third quarter 2023 financial results on Tuesday, November 14, 2023, prior to the U.S. financial markets open.

Who will host the conference call and live webcast to discuss the financial results?

Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host the conference call and live webcast at 8:30 a.m. EST.

How can analysts and investors access the conference call and webcast?

Analysts and investors may utilize the provided toll-free and international phone numbers or access the webcast through the Company's website in the 'Investors' section.

ReWalk Robotics Ltd.

NASDAQ:RWLK

RWLK Rankings

RWLK Latest News

RWLK Stock Data

8.92M
58.82M
1.96%
20.72%
2.27%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
P O Box 161

About RWLK

exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the